|
Corcept Therapeutics Incorporated (CORT) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Corcept Therapeutics Incorporated (CORT) Bundle
Stürzen Sie Ihre Analyse und verbessern Sie die Präzision mit unserem (CORT) DCF -Taschenrechner! Mit diesem Tool können Sie mit aktuellen Daten und anpassbaren Annahmen anpassbaren Annahmen ausgestattet sein, und ermöglicht Ihnen, wie ein erfahrener Investor prognostiziert, analysieren und value (CORT).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 353.9 | 366.0 | 401.9 | 482.4 | 675.0 | 738.8 | 808.7 | 885.1 | 968.8 | 1,060.4 |
| Revenue Growth, % | 0 | 3.42 | 9.8 | 20.04 | 39.94 | 9.45 | 9.45 | 9.45 | 9.45 | 9.45 |
| EBITDA | 130.4 | 124.5 | 112.6 | 108.3 | 137.0 | 209.3 | 229.1 | 250.7 | 274.4 | 300.4 |
| EBITDA, % | 36.86 | 34.01 | 28.03 | 22.46 | 20.29 | 28.33 | 28.33 | 28.33 | 28.33 | 28.33 |
| Depreciation | 2.2 | 3.1 | 3.0 | 1.0 | .0 | 3.6 | 3.9 | 4.3 | 4.7 | 5.1 |
| Depreciation, % | 0.63215 | 0.83803 | 0.73882 | 0.21601 | 0 | 0.485 | 0.485 | 0.485 | 0.485 | 0.485 |
| EBIT | 128.2 | 121.4 | 109.7 | 107.3 | 137.0 | 205.7 | 225.2 | 246.5 | 269.8 | 295.2 |
| EBIT, % | 36.23 | 33.17 | 27.29 | 22.24 | 20.29 | 27.84 | 27.84 | 27.84 | 27.84 | 27.84 |
| Total Cash | 476.9 | 335.8 | 436.6 | 368.2 | 383.3 | 627.8 | 687.2 | 752.1 | 823.2 | 901.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 26.2 | 27.6 | 31.1 | 41.1 | 54.0 | 57.9 | 63.4 | 69.4 | 76.0 | 83.1 |
| Account Receivables, % | 7.4 | 7.55 | 7.73 | 8.53 | 8 | 7.84 | 7.84 | 7.84 | 7.84 | 7.84 |
| Inventories | 21.2 | 18.0 | 17.0 | 7.7 | 12.4 | 27.4 | 30.0 | 32.9 | 36.0 | 39.4 |
| Inventories, % | 5.98 | 4.9 | 4.24 | 1.6 | 1.84 | 3.71 | 3.71 | 3.71 | 3.71 | 3.71 |
| Accounts Payable | 10.6 | 6.9 | 12.0 | 17.4 | 15.4 | 20.3 | 22.2 | 24.3 | 26.6 | 29.1 |
| Accounts Payable, % | 2.98 | 1.89 | 2.98 | 3.61 | 2.28 | 2.75 | 2.75 | 2.75 | 2.75 | 2.75 |
| Capital Expenditure | -1.2 | -.5 | -.4 | -.1 | -2.2 | -1.4 | -1.5 | -1.6 | -1.8 | -2.0 |
| Capital Expenditure, % | -0.34984 | -0.12815 | -0.10277 | -0.02881576 | -0.32176 | -0.18627 | -0.18627 | -0.18627 | -0.18627 | -0.18627 |
| Tax Rate, % | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 | 13.47 |
| EBITAT | 103.3 | 109.3 | 95.7 | 91.4 | 118.5 | 176.8 | 193.5 | 211.7 | 231.8 | 253.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 67.5 | 110.0 | 100.8 | 97.0 | 96.8 | 164.9 | 189.7 | 207.7 | 227.3 | 248.8 |
| WACC, % | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 | 6.78 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 845.5 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 257 | |||||||||
| Terminal Value | 7,854 | |||||||||
| Present Terminal Value | 5,658 | |||||||||
| Enterprise Value | 6,503 | |||||||||
| Net Debt | -121 | |||||||||
| Equity Value | 6,624 | |||||||||
| Diluted Shares Outstanding, MM | 113 | |||||||||
| Equity Value Per Share | 58.37 |
What You Will Get
- Real CORT Financial Data: Pre-filled with Corcept Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Corcept Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life CORT Financials: Pre-filled historical and projected data for Corcept Therapeutics Incorporated (CORT).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Corcept’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Corcept’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Corcept Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Corcept Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Corcept Therapeutics Incorporated (CORT)?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses tailored for Corcept Therapeutics.
- Flexible Inputs: Modify yellow-highlighted cells to explore different financial scenarios for (CORT).
- In-Depth Analysis: Automatically computes Corcept's intrinsic value and Net Present Value.
- Preloaded Information: Historical and projected data provide reliable starting points for (CORT).
- High-Quality Standards: Perfect for financial analysts, investors, and business consultants focusing on (CORT).
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions regarding Corcept Therapeutics stock (CORT).
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for Corcept Therapeutics.
- Consultants: Provide clients with accurate and timely valuation insights related to Corcept Therapeutics.
- Business Owners: Learn about the valuation of biopharmaceutical companies like Corcept to inform your own business strategy.
- Finance Students: Explore real-world data and scenarios to master valuation techniques using Corcept Therapeutics as a case study.
What the Template Contains
- Pre-Filled Data: Contains Corcept Therapeutics' historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with real-time calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC using customized inputs.
- Key Financial Ratios: Evaluate Corcept's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth rates, margins, and tax assumptions.
- Clear Dashboard: Visuals and tables summarizing critical valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.